Clinical Trial Update: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of JNJ-69086420, an Actinium-225-labeled antibody targeting hK2, for advanced prostate cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• JNJ-69086420

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostatic Neoplasms, Adenocarcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING